These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 28121940)

  • 1. Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: A case report.
    Sarfaty M; Moore A; Dudnik E; Peled N
    Medicine (Baltimore); 2017 Jan; 96(4):e5951. PubMed ID: 28121940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: Case report.
    Chen YH; Liu FC; Hsu CH; Chian CF
    Medicine (Baltimore); 2017 Jul; 96(27):e7350. PubMed ID: 28682883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence.
    Lim JS; Soo RA
    Ther Adv Respir Dis; 2016 Oct; 10(5):444-54. PubMed ID: 27480166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy.
    Fujimoto D; Yoshioka H; Kataoka Y; Morimoto T; Hata T; Kim YH; Tomii K; Ishida T; Hirabayashi M; Hara S; Ishitoko M; Fukuda Y; Hwang MH; Sakai N; Fukui M; Nakaji H; Morita M; Mio T; Yasuda T; Sugita T; Hirai T
    J Thorac Oncol; 2019 Mar; 14(3):468-474. PubMed ID: 30468872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer.
    Rounds A; Kolesar J
    Am J Health Syst Pharm; 2015 Nov; 72(21):1851-5. PubMed ID: 26490818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report.
    Ozaki Y; Shindoh J; Miura Y; Nakajima H; Oki R; Uchiyama M; Masuda J; Kinowaki K; Kondoh C; Tanabe Y; Tanaka T; Haruta S; Ueno M; Kitano S; Fujii T; Udagawa H; Takano T
    BMC Cancer; 2017 Nov; 17(1):778. PubMed ID: 29162045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer.
    Feng Y; Wang X; Bajaj G; Agrawal S; Bello A; Lestini B; Finckenstein FG; Park JS; Roy A
    Clin Cancer Res; 2017 Sep; 23(18):5394-5405. PubMed ID: 28916617
    [No Abstract]   [Full Text] [Related]  

  • 8. Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression.
    Tanizaki J; Hayashi H; Kimura M; Tanaka K; Takeda M; Shimizu S; Ito A; Nakagawa K
    Lung Cancer; 2016 Dec; 102():44-48. PubMed ID: 27987588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma.
    Oliveira LJC; Gongora ABL; Barbosa FG; Dos Anjos CH; Munhoz RR
    J Immunother Cancer; 2018 Nov; 6(1):130. PubMed ID: 30482243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of tumor flare after nivolumab treatment in patients with irradiated field recurrence.
    Yoshida T; Furuta H; Hida T
    Med Oncol; 2017 Mar; 34(3):34. PubMed ID: 28138869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients.
    Garde-Noguera J; Martin-Martorell P; De Julián M; Perez-Altozano J; Salvador-Coloma C; García-Sanchez J; Insa-Molla A; Martín M; Mielgo-Rubio X; Marin-Liebana S; Blasco-Cordellat A; Blasco-Molla S; Gironés R; Marquez-Medina D; Aparisi F; Cerda MCB; Macia-Escalante S; Sánchez A; Juan-Vidal O
    Clin Transl Oncol; 2018 Aug; 20(8):1072-1079. PubMed ID: 29368144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Katz SI; Hammer M; Bagley SJ; Aggarwal C; Bauml JM; Thompson JC; Nachiappan AC; Simone CB; Langer CJ
    J Thorac Oncol; 2018 Jul; 13(7):978-986. PubMed ID: 29738824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
    Li H; Ma W; Yoneda KY; Moore EH; Zhang Y; Pu LL; Frampton GM; Molmen M; Stephens PJ; Li T
    J Hematol Oncol; 2017 Feb; 10(1):64. PubMed ID: 28245875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased Tim-3
    Kato R; Yamasaki M; Urakawa S; Nishida K; Makino T; Morimoto-Okazawa A; Kawashima A; Iwahori K; Suzuki S; Ueda R; Mori M; Satoh T; Doki Y; Wada H
    Cancer Immunol Immunother; 2018 Nov; 67(11):1673-1683. PubMed ID: 30128737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
    Brahmer J; Reckamp KL; Baas P; Crinò L; Eberhardt WE; Poddubskaya E; Antonia S; Pluzanski A; Vokes EE; Holgado E; Waterhouse D; Ready N; Gainor J; Arén Frontera O; Havel L; Steins M; Garassino MC; Aerts JG; Domine M; Paz-Ares L; Reck M; Baudelet C; Harbison CT; Lestini B; Spigel DR
    N Engl J Med; 2015 Jul; 373(2):123-35. PubMed ID: 26028407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor pseudoprogression during nivolumab immunotherapy for lung cancer.
    Mayoral M; Castañer E; Gallardo X; Andreu M; Dalmau E; Garcia Y
    Radiologia (Engl Ed); 2019; 61(6):498-505. PubMed ID: 31300214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
    Hanna N; Johnson D; Temin S; Baker S; Brahmer J; Ellis PM; Giaccone G; Hesketh PJ; Jaiyesimi I; Leighl NB; Riely GJ; Schiller JH; Schneider BJ; Smith TJ; Tashbar J; Biermann WA; Masters G
    J Clin Oncol; 2017 Oct; 35(30):3484-3515. PubMed ID: 28806116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy: A Report From the US Food and Drug Administration.
    Kazandjian D; Khozin S; Blumenthal G; Zhang L; Tang S; Libeg M; Kluetz P; Sridhara R; Keegan P; Pazdur R
    JAMA Oncol; 2016 Jan; 2(1):118-22. PubMed ID: 26470053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central Nervous System Pseudoprogression With Nivolumab in a Patient With Squamous Cell Lung Cancer Followed by Prolonged Response.
    Swami U; Smith M; Zhang J
    J Thorac Oncol; 2018 Sep; 13(9):e183-e184. PubMed ID: 30166022
    [No Abstract]   [Full Text] [Related]  

  • 20. Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer.
    Kobayashi H; Omori S; Nakashima K; Wakuda K; Ono A; Kenmotsu H; Naito T; Murakami H; Endo M; Takahashi T
    Int J Clin Oncol; 2017 Aug; 22(4):690-697. PubMed ID: 28382561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.